Medexus Pharmaceuticals Financials

MDP Stock   2.86  0.12  4.38%   
We recommend to make use of analysis of Medexus Pharmaceuticals fundamentals to see if markets are presently mispricing the entity. We were able to interpolate data for thirty available fundamentals for Medexus Pharmaceuticals, which can be compared to its peers in the industry. The stock experiences a very speculative upward sentiment. Check odds of Medexus Pharmaceuticals to be traded at 3.58 in 90 days.
 
Yuan Drop
 
Covid
 
Interest Hikes

Medexus Pharmaceuticals Balance Sheet Chart

At this time, Medexus Pharmaceuticals' Cash And Short Term Investments are very stable compared to the past year. As of the 15th of February 2026, Liabilities And Stockholders Equity is likely to grow to about 207.5 M, while Retained Earnings are likely to drop (58.6 M).
Key indicators impacting Medexus Pharmaceuticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.610.64
Sufficiently Down
Slightly volatile
Current Ratio0.90.95
Notably Down
Slightly volatile
  

Medexus Pharmaceuticals Stock Summary

Medexus Pharmaceuticals competes with Cardiol Therapeutics. Medexus Pharmaceuticals is entity of Canada. It is traded as Stock on TO exchange.
Foreign Associate
  USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeToronto Exchange
ISINCA58410Q2036
Business Address10 King Street
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.medexus.com
Phone877 422 5242
You should never invest in Medexus Pharmaceuticals without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medexus Stock, because this is throwing your money away. Analyzing the key information contained in Medexus Pharmaceuticals' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Medexus Pharmaceuticals Key Financial Ratios

Medexus Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Medexus Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Medexus Pharmaceuticals over time and compare it to other companies across industries.

Medexus Pharmaceuticals Key Balance Sheet Accounts

202120222023202420252026 (projected)
Total Assets139.2M161.3M155.7M171.8M197.6M207.5M
Other Current Liab26.2M15.9M41.4M53.2M61.2M64.3M
Net Debt56.1M77.1M44.6M13.2M15.2M18.9M
Retained Earnings(65.2M)(64.0M)(64.2M)(62.0M)(55.8M)(58.6M)
Cash12.5M17.7M5.3M24.0M27.6M28.9M
Other Current Assets3.3M7.4M12.4M8.0M9.2M9.7M
Total Liab151.8M187.7M125.4M119.7M137.6M71.8M
Total Current Assets49.1M73.0M72.5M80.6M92.7M97.3M
Accounts Payable15.1M10.2M7.8M5.7M6.6M7.3M
Net Receivables14.4M29.7M24.0M13.3M15.3M11.9M
Inventory21.4M22.8M30.8M35.3M40.6M42.6M
Short Term Debt18.8M57.7M15.7M37.0M42.5M44.7M
Intangible Assets76.6M70.4M64.1M71.6M82.3M43.7M
Other Assets1.6M6.8M8.0M9.0M10.3M10.8M
Common Stock68.7M69.0M76.4M96.1M110.5M116.0M
Long Term Debt39.8M27.4M34.2M198K227.7K216.3K
Long Term Debt Total39.8M27.4M34.2M198K227.7K216.3K
Capital Surpluse10.4M11.3M12.0M12.0M13.8M9.5M
Cash And Equivalents10.0M13.1M5.3M24.0M27.6M28.9M
Net Tangible Assets(55.5M)(69.0M)(69.5M)(58.2M)(52.4M)(55.0M)
Net Invested Capital72.7M92.5M80.2M89.3M102.7M70.3M
Short Long Term Debt15.0M42.7M15.7M37.0M42.5M44.7M
Net Working Capital1.0M(10.5M)6.3M(16.7M)(15.1M)(14.3M)
Other Liab35.7M56.3M33.5M28.0M25.2M30.9M
Good Will10.7M10.3M10.3M10.0M11.5M10.8M
Capital Stock68.7M69.0M76.4M96.1M110.5M73.1M

Medexus Pharmaceuticals Key Income Statement Accounts

202120222023202420252026 (projected)
Operating Income(15.0M)7.6M10.8M8.2M9.5M9.9M
Ebitda15.2M16.1M19.3M16.8M19.3M20.3M
Income Before Tax(3.8M)(5.0M)106K1.4M1.3M1.4M
Net Income(2.9M)1.2M(214K)2.2M2.0M2.1M
Total Revenue76.7M108.1M113.1M108.3M124.6M130.8M
Gross Profit37.9M60.0M59.5M56.6M65.1M68.3M
Research Development7.3M2.9M8.0M8.3M9.5M4.8M
Cost Of Revenue38.8M48.1M53.5M51.7M59.5M62.5M
Interest Expense12.2M13.6M13.4M8.2M9.4M7.1M
Ebit7.8M8.1M13.5M9.6M11.1M11.6M
Income Tax Expense(941K)(6.3M)320K(807K)(726.3K)(762.6K)
Interest Income11.2M12.7M10.7M6.8M7.8M5.2M
Net Interest Income(12.2M)(13.6M)(13.4M)(8.2M)(7.4M)(7.7M)
Tax Provision(941K)(6.3M)320K(807K)(726.3K)(762.6K)

Medexus Pharmaceuticals Key Cash Accounts

202120222023202420252026 (projected)
Change In Cash(8.7M)3.1M(7.8M)18.7M21.5M22.6M
Free Cash Flow(8.9M)(1.8M)18.4M21.3M24.5M25.7M
Capital Expenditures7.7M362K266K2.7M3.1M2.0M
Net Income(2.9M)1.2M(214K)2.2M2.0M2.1M
End Period Cash Flow10.0M13.1M5.3M24.0M27.6M28.9M
Other Non Cash Items(11.3M)11.6M9.2M9.2M10.5M11.1M
Change To Inventory(8.4M)(2.0M)(9.1M)(4.6M)(4.1M)(3.9M)
Depreciation6.1M6.1M5.8M7.2M8.3M8.7M
Investments(8.2M)(1.7M)(3.5M)(6.0M)(6.9M)(7.2M)
Net Borrowings3.7M10.7M(26.4M)(14.2M)(12.8M)(12.2M)
Change To Netincome633K27.1M(9.2M)6.5M7.5M4.9M

Medexus Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Medexus Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Medexus Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medexus Pharmaceuticals competition to find correlations between indicators driving Medexus Pharmaceuticals's intrinsic value. More Info.
Medexus Pharmaceuticals is regarded second in return on equity category among its peers. It is considered to be number one stock in return on asset category among its peers . At this time, Medexus Pharmaceuticals' Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all model that can be used if you cannot value Medexus Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Medexus Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Medexus Pharmaceuticals Total Assets Over Time

Most indicators from Medexus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Medexus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medexus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
At this time, Medexus Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 15th of February 2026, Issuance Of Capital Stock is likely to grow to about 23.1 M, while Tax Provision is likely to drop (762.6 K).
 2023 2024 2025 2026 (projected)
Gross Profit59.5M56.6M65.1M68.3M
Total Revenue113.1M108.3M124.6M130.8M

Medexus Pharmaceuticals fundamental ratios Correlations

0.850.930.90.68-0.910.780.750.30.880.540.890.980.990.680.710.830.860.890.760.850.950.860.930.850.96
0.850.890.930.36-0.750.660.690.30.850.470.60.890.780.620.30.510.540.960.360.530.970.780.670.950.95
0.930.890.880.66-0.850.710.690.310.860.510.820.950.880.650.480.80.70.940.550.770.960.970.80.930.95
0.90.930.880.33-0.740.830.850.350.860.520.650.930.860.770.390.540.630.880.490.570.930.790.730.880.95
0.680.360.660.33-0.740.240.140.130.560.370.860.60.690.230.770.940.80.510.750.890.550.680.750.450.52
-0.91-0.75-0.85-0.74-0.74-0.71-0.65-0.3-0.76-0.59-0.91-0.9-0.9-0.58-0.72-0.87-0.81-0.83-0.76-0.86-0.84-0.77-0.88-0.75-0.86
0.780.660.710.830.24-0.710.990.280.580.480.630.820.780.80.460.530.570.660.570.530.70.660.670.650.8
0.750.690.690.850.14-0.650.990.280.590.460.560.80.750.820.370.440.520.650.50.440.70.620.620.650.8
0.30.30.310.350.13-0.30.280.280.270.930.260.320.260.160.070.220.220.310.140.230.310.280.270.30.3
0.880.850.860.860.56-0.760.580.590.270.460.740.90.840.770.50.680.70.870.510.740.910.770.760.880.86
0.540.470.510.520.37-0.590.480.460.930.460.550.550.520.340.330.480.490.50.410.480.510.460.540.460.51
0.890.60.820.650.86-0.910.630.560.260.740.550.850.910.570.820.960.930.70.860.940.760.790.960.640.77
0.980.890.950.930.6-0.90.820.80.320.90.550.850.960.770.610.780.780.920.670.810.960.870.870.90.98
0.990.780.880.860.69-0.90.780.750.260.840.520.910.960.690.780.840.910.810.840.850.890.80.950.760.92
0.680.620.650.770.23-0.580.80.820.160.770.340.570.770.690.360.470.510.620.430.510.650.580.560.660.7
0.710.30.480.390.77-0.720.460.370.070.50.330.820.610.780.360.80.880.390.970.840.480.420.830.280.52
0.830.510.80.540.94-0.870.530.440.220.680.480.960.780.840.470.80.860.660.810.970.690.810.880.60.69
0.860.540.70.630.8-0.810.570.520.220.70.490.930.780.910.510.880.860.570.940.850.70.640.960.490.71
0.890.960.940.880.51-0.830.660.650.310.870.50.70.920.810.620.390.660.570.420.690.970.850.710.980.96
0.760.360.550.490.75-0.760.570.50.140.510.410.860.670.840.430.970.810.940.420.810.530.490.880.310.59
0.850.530.770.570.89-0.860.530.440.230.740.480.940.810.850.510.840.970.850.690.810.710.740.890.630.71
0.950.970.960.930.55-0.840.70.70.310.910.510.760.960.890.650.480.690.70.970.530.710.870.80.950.98
0.860.780.970.790.68-0.770.660.620.280.770.460.790.870.80.580.420.810.640.850.490.740.870.730.870.86
0.930.670.80.730.75-0.880.670.620.270.760.540.960.870.950.560.830.880.960.710.880.890.80.730.640.82
0.850.950.930.880.45-0.750.650.650.30.880.460.640.90.760.660.280.60.490.980.310.630.950.870.640.93
0.960.950.950.950.52-0.860.80.80.30.860.510.770.980.920.70.520.690.710.960.590.710.980.860.820.93
Click cells to compare fundamentals

Medexus Pharmaceuticals Account Relationship Matchups

Medexus Pharmaceuticals fundamental ratios Accounts

202120222023202420252026 (projected)
Total Assets139.2M161.3M155.7M171.8M197.6M207.5M
Other Current Liab26.2M15.9M41.4M53.2M61.2M64.3M
Net Debt56.1M77.1M44.6M13.2M15.2M18.9M
Retained Earnings(65.2M)(64.0M)(64.2M)(62.0M)(55.8M)(58.6M)
Cash12.5M17.7M5.3M24.0M27.6M28.9M
Other Current Assets3.3M7.4M12.4M8.0M9.2M9.7M
Total Liab151.8M187.7M125.4M119.7M137.6M71.8M
Total Current Assets49.1M73.0M72.5M80.6M92.7M97.3M
Accounts Payable15.1M10.2M7.8M5.7M6.6M7.3M
Net Receivables14.4M29.7M24.0M13.3M15.3M11.9M
Inventory21.4M22.8M30.8M35.3M40.6M42.6M
Short Term Debt18.8M57.7M15.7M37.0M42.5M44.7M
Intangible Assets76.6M70.4M64.1M71.6M82.3M43.7M
Other Assets1.6M6.8M8.0M9.0M10.3M10.8M
Common Stock68.7M69.0M76.4M96.1M110.5M116.0M
Long Term Debt39.8M27.4M34.2M198K227.7K216.3K
Long Term Debt Total39.8M27.4M34.2M198K227.7K216.3K
Capital Surpluse10.4M11.3M12.0M12.0M13.8M9.5M
Cash And Equivalents10.0M13.1M5.3M24.0M27.6M28.9M
Net Tangible Assets(55.5M)(69.0M)(69.5M)(58.2M)(52.4M)(55.0M)
Net Invested Capital72.7M92.5M80.2M89.3M102.7M70.3M
Short Long Term Debt15.0M42.7M15.7M37.0M42.5M44.7M
Net Working Capital1.0M(10.5M)6.3M(16.7M)(15.1M)(14.3M)
Other Liab35.7M56.3M33.5M28.0M25.2M30.9M
Good Will10.7M10.3M10.3M10.0M11.5M10.8M
Capital Stock68.7M69.0M76.4M96.1M110.5M73.1M
Today, most investors in Medexus Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Medexus Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Medexus Pharmaceuticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(0.0229)

At this time, Medexus Pharmaceuticals' Price Earnings To Growth Ratio is very stable compared to the past year.

Medexus Pharmaceuticals February 15, 2026 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Medexus Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medexus Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medexus Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Medexus Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medexus Pharmaceuticals's daily price indicators and compare them against related drivers.

Other Information on Investing in Medexus Stock

Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.